Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K142723
    Date Cleared
    2015-03-31

    (189 days)

    Product Code
    Regulation Number
    862.1205
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    K962559

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The ADVIA Centaur® Cortisol (COR) Assay is for in vitro diagnostic use in the quantitative determination of cortisol in serum or urine using the ADVIA Centaur XP system. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.

    Device Description

    The ADVIA Centaur Cortisol assay is a competitive immunoassay using direct chemiluminescent technology. Results are determined using a calibration curve that is generated specifically on each instrument by a 2-point calibration and a master curve with the reagent bar code. The ADVIA Centaur Cortisol Assay is intended for use on the ADVIA Centaur Family of analyzers. The ADVIA Centaur Calibrator E is a set of 2 level calibrators for the assay. Siemens recommends the use of commercially available quality control materials with at least two levels (low and high).

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the ADVIA Centaur® Cortisol (COR) Assay, based on the provided FDA 510(k) summary:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance Criteria CategorySpecific Criteria/TestAcceptance Criteria (Implicit from satisfactory results)Reported Device Performance (Summary)Comment
    PrecisionCLSI EP05-A2 protocol (20-day study, 2 reps/run, 2 runs/day)Within-Lab %CV should be acceptableSerum: 4.4% - 6.0% (Controls), 4.9% - 5.3% (Samples)
    Direct Urine: 6.8% - 9.1%
    Extracted Urine: 6.8% - 9.2%Performance appears to be within generally accepted clinical chemistry precision standards, demonstrating good reproducibility.
    Linearity/Assay RangeLinearity across the measuring range (EP06-A)% Recovery should be acceptable, high r² (correlation)Serum: Y=1.057x - 0.051, r²=0.9991, % Recovery 96.0-109.3%
    Direct Urine: Y=1.011x + 0.090, r²=0.9975, % Recovery 94.7-119.6%
    Extracted Urine: Y=0.914x + 0.017, r²=0.9997, % Recovery 82.7-100.9%Strong linearity demonstrated with high r² values close to 1, indicating a good proportional relationship between expected and observed values over the claimed analytical range. The urine recoveries showed a slightly wider range but were still deemed acceptable.
    Analytical Detection LimitsLoB, LoD, LoQ (EP17-A2)Values should be below claimed measuring rangeLoB: Serum 0.06 µg/dL, Direct Urine 0.19 µg/dL, Extracted Urine 0.18 µg/dL
    LoD: Serum 0.14 µg/dL, Direct Urine 0.45 µg/dL, Extracted Urine 0.44 µg/dL
    LoQ: Serum 0.31 µg/dL, Direct Urine 0.48 µg/dL, Extracted Urine 0.44 µg/dLThe determined detection limits are well below the lower end of the claimed measuring range (0.50 µg/dL), supporting the device's ability to accurately measure low concentrations.
    Analytical Specificity (Interference)Endogenous substances (EP07-A2)% Interference ≤ 10%All tested endogenous substances (Hemoglobin, Triglycerides, Bilirubin, Protein, NaCl, Urea, Creatinine, Glucose, Boric Acid) showed % Interference within -5% to 5%.The device demonstrates good resistance to interference from common endogenous substances in both serum and urine, ensuring reliable results in various patient samples.
    Analytical Specificity (Cross-reactivity)Potential cross-reactant compoundsLow cross-reactivity with structurally similar compoundsMost compounds showed low cross-reactivity (
    Ask a Question

    Ask a specific question about this device

    K Number
    K021218
    Date Cleared
    2002-09-09

    (145 days)

    Product Code
    Regulation Number
    862.1205
    Reference & Predicate Devices
    Why did this record match?
    Reference Devices :

    K962559

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Immunological in vitro assay for the quantitative determination of cortisol in human serum, plasma and urine. The determination of cortisol is used for the recognition and treatment of functional disorders of the adrenal gland.

    The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Roche Elecsys® 1010 / 2010 and Modular Analytics E170 (Elecsys module) Immunoassay Analyzers.

    Device Description

    The ELECSYS® Cortisol Assay a two step sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2-point calibration and a master curve provided with the reagent bar code.

    AI/ML Overview

    The information provided describes the Elecsys® Cortisol Assay and its substantial equivalence to a predicate device (Bayer Diagnostics ACS:180 Cortisol Assay). It focuses on comparing the new device's performance characteristics to the predicate device to demonstrate substantial equivalence, rather than detailing a specific study proving the device meets acceptance criteria with predefined thresholds. Therefore, some of the requested information cannot be fully extracted as it pertains to a typical clinical validation study with explicitly stated acceptance criteria and a detailed study design.

    Here's the breakdown of what can be extracted and what is not available in the provided text:

    1. Table of acceptance criteria and the reported device performance:

    The document doesn't explicitly state "acceptance criteria" through specific numerical thresholds for each performance characteristic. Instead, it demonstrates performance by comparing the new device's data directly to that of the predicate device, implying that performance comparable to the legally marketed predicate device is the de facto acceptance criteria for substantial equivalence.

    FeatureAcceptance Criteria (Implied: Comparable to Predicate)New Device (ELECSYS Cortisol) Reported PerformancePredicate Device (Bayer ACS:180 Cortisol) Reported Performance
    Intra-assay precision (%CV) (Urine)Comparable to Predicate's Intra-assay precision• 2.2% at 22.3 µg/dl
    • 2.3% at 33.2 µg/dl
    • 2.9% at 41.9 µg/dl
    • 2.3% at 61.0 µg/dl• 5.7% at 3.04 µg/dl
    • 5.1% at 5.43 µg/dl
    • 4.5% at 14.90 µg/dl
    • 6.4% at 18.98 µg/dl
    • 7.0% at 31.79 µg/dl
    • 7.5% at 38.67 µg/dl
    Interassay precision (%CV) (Urine)N/A (Predicate data not fully provided)• 2.5% at 23.2 µg/dl
    • 3.2% at 33.4 µg/dl
    • 2.5% at 42.1 µg/dl
    • 1.8% at 58.9 µg/dl
    Control: 4.7% at 2.82 µg/dlN/A
    Total precision (%CV)Comparable to Predicate's Total precisionN/A• 9.1% at 3.04 µg/dl
    • 8.0% at 5.43 µg/dl
    • 6.4% at 14.90 µg/dl
    • 8.2% at 18.98 µg/dl
    • 9.2% at 31.79 µg/dl
    • 9.7% at 38.67 µg/dl
    Functional sensitivityComparable or better than Predicate's functional sensitivity
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1